Generali Investments Management Co LLC Decreases Stock Holdings in Veeva Systems Inc. $VEEV

Generali Investments Management Co LLC lowered its stake in Veeva Systems Inc. (NYSE:VEEV) by 72.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 6,530 shares of the technology company’s stock after selling 16,903 shares during the quarter. Generali Investments Management Co LLC’s holdings in Veeva Systems were worth $1,159,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SHP Wealth Management purchased a new stake in shares of Veeva Systems during the fourth quarter worth about $26,000. Activest Wealth Management raised its position in shares of Veeva Systems by 3,175.0% during the 4th quarter. Activest Wealth Management now owns 131 shares of the technology company’s stock worth $29,000 after purchasing an additional 127 shares during the last quarter. Arlington Trust Co LLC purchased a new position in Veeva Systems in the 2nd quarter valued at about $29,000. MV Capital Management Inc. purchased a new position in Veeva Systems in the 4th quarter valued at about $30,000. Finally, Reflection Asset Management acquired a new stake in Veeva Systems in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on VEEV. Mizuho cut their price objective on Veeva Systems from $295.00 to $270.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. BMO Capital Markets decreased their target price on Veeva Systems from $220.00 to $175.00 and set a “market perform” rating on the stock in a research report on Thursday, June 4th. BTIG Research reaffirmed a “buy” rating and issued a $340.00 price target on shares of Veeva Systems in a research note on Thursday, June 4th. Zacks Research cut Veeva Systems from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group reduced their price objective on Veeva Systems from $235.00 to $220.00 and set a “hold” rating for the company in a research note on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $247.08.

Veeva Systems Price Performance

Shares of NYSE VEEV opened at $234.27 on Tuesday. The company has a 50 day simple moving average of $184.73 and a 200-day simple moving average of $179.95. The company has a market capitalization of $38.05 billion, a P/E ratio of 41.76, a P/E/G ratio of 0.99 and a beta of 0.92. Veeva Systems Inc. has a 1 year low of $148.05 and a 1 year high of $310.50.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings data on Wednesday, June 3rd. The technology company reported $2.24 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. Veeva Systems had a return on equity of 13.72% and a net margin of 28.37%.The firm had revenue of $882.95 million for the quarter, compared to analysts’ expectations of $857.73 million. During the same period in the prior year, the firm posted $1.97 earnings per share. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. As a group, research analysts expect that Veeva Systems Inc. will post 6.65 EPS for the current year.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.